Startup Targets Aging-Related Diseases With New Partnership
Unity Biotechnology will collaborate with Chinese company Ascentage Pharma to develop drugs that will go after dead cells that damage healthy tissue.
The San Francisco Business Journal:
Aging-Defying North Bay Startup Lands Deal With Chinese Drug Company
Startup Unity Biotechnology Inc. will work with a Chinese company to develop drugs aimed at clearing dead cells thought to play a role in a range of aging-related diseases. Financial terms of the deal were not disclosed. But Ascentage Pharma will buy a stake in Unity, which is based at the Buck Institute for Research on Aging in Novato, and Unity will make an investment in Ascentage. What’s more, the collaboration is worldwide, but the companies will form a joint venture to develop and sell so-called “senolytic” drugs in China. (Leuty, 4/25)
In other pharmaceutical news —
The San Francisco Business Journal:
Peninsula Drug Developer Scores Comeback Win For Cancer-Fighting Tablet
Exelixis Inc. scored the second FDA approval for its cabozantinib cancer-fighting franchise Monday, this time with a tablet against the most common form of adult kidney cancer. (Leuty, 4/25)